For example, MK1775 is currently under evaluation in combination with either gemcitabine or paclitaxel and carboplatin to treat refractory or resistant ovarian cancer or platinum-sensitive p53 mutated ovarian cancer. Here, TP53 is linked to ovarian carcinoma.